Comparison of bone marrow biopsy and fluorodeoxyglucose-positron emission tomography for the assessment of bone marrow infiltration in children with Hodgkin’s lymphoma

Abstract

Purpose To compare bone marrow biopsy (BMB) with [18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (PET/CT) imaging in the demonstration of bone marrow involvement in children with Hodgkin’s Lymphoma (HL) and to investigate the effectiveness of PET/CT imaging and thus the necessity for BMB at staging.

Methods Pediatric patients with HL, who underwent both bilateral iliac BMB and PET/CT imaging at disease staging were retrospectively analyzed. In determining bone marrow involvement (BMinv), BMB and/or first/follow-up PET/CT imaging were eligible for review.

Results Fifty-six patients were included. BMinv was detected by PET/CT imaging in 6/56 (10.7%), whereas the proportion was 3/56 (5.3%) in BMB specimens. Bone marrow biopsies and PET/CT images were concordant in 53/56 (94.6%) patients with BMB specimens missing three cases of BMinv detected by PET/CT. When diagnostic accuracy was calculated, sensitivity, specificity, positive predictive value and negative predictive values for PET/CT were 100%, 100%, 100%, 100%, respectively, and the same values for BMB were 50%, 100%, 100%, 94.3%, respectively.

Conclusions The results of PET/CT and BMB for staging of pediatric HL patients were compatible, and PET/CT imaging was found to provide high diagnostic performance in determining BMinv. In keeping with earlier research, the current study showed that BMB may not be necessary in every patient at staging, and should be reserved for cases where PET/CT is inconclusive.

Zusammenfassung

Ziel Vergleich der Knochenmarkbiopsie (KMB) mit [18F]Fluoro-2-Desoxyglukose-Positronen-Emissions-Tomografie/Computertomografie (PET/CT) zum Nachweis der Knochenmarkinfiltration bei Kindern mit Hodgkin-Lymphom (HL) und um die Wirksamkeit von PET/CT und damit die Notwendigkeit von KMB beim Staging zu untersuchen.

Methoden Pädiatrische Patienten mit HL, die sich sowohl einer bilateralen iliakalen KMB als auch einer PET/CT-Bildgebung für das Staging unterzogen, wurden retrospektiv analysiert. Bei der Bestimmung der Knochenmarkinfiltration (KMinv) wurden KMB und/oder Erst-/Folge-PET/CT-Bildgebung berücksichtigt.

Ergebnisse 56 Patienten wurden in die Studie eingeschlossen. KMinv wurde in der PET/CT-Bildgebung bei 6/56 (10,7%) Patienten nachgewiesen, verglichen mit 3/56 (5,3%) Patienten in den KMB-Proben. PET/CT- und KMB-Ergebnisse waren bei 53/56 Patienten kompatibel, 3 Patienten mit KMinv bei PET/CT wurden bei KMB nicht erkannt. Bei der Berechnung der diagnostischen Genauigkeit betrugen Sensitivität, Spezifität, positiver Vorhersagewert und negativer Vorhersagewert für PET/CT 100%, 100%, 100% bzw. 100%, und die gleichen Werte für BMB waren 50%, 100%, 100% bzw. 94,3%.

Schlussfolgerungen Die Ergebnisse von PET/CT und BMB für das Staging von pädiatrischen HL-Patienten waren kompatibel, und die PET/CT-Bildgebung erwies sich als hochgradig diagnostisch bei der Bestimmung einer Knochenmarkinfiltration. In Übereinstimmung mit früheren Studien zeigte die aktuelle Studie, dass eine KMB nicht bei jedem Patienten zum Staging erforderlich sein könnte und Fällen vorbehalten bleiben sollte, in denen die PET/CT nicht schlüssig ist.

Schlüsselwörter

Hodgkin-Lymphom - Positronen-Emissions-Tomographie - Knochenmarkbiopsie - Lymphom-Staging - Kind

Keywords

Hodgkin’s lymphoma - Positron emission tomography - Bone marrow biopsy - Lymphoma staging - child

Publikationsverlauf

Eingereicht: 13. Juli 2022

Angenommen nach Revision: 03. November 2022

Artikel online veröffentlicht:
06. Februar 2023

• References

• 1 Smith CM, Friedman DL. Hodgkin Lymphoma. In: Fish JD, Lipton JM, Lanzkowsky P. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. Elsevier; 2021: 459-473
• 2 Kahn JM, Pei Q, Friedman DL. et al. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials. Lancet Haematol 2022; 9 (01) e49-e57
• 3 El-Galaly TC, Cottereau AS, Condoluci A. et al. Hodgkin Lymphoma: Recent Progress in Overall Management. In: Gallamini A, Juweid M. Lymphoma [Internet], Chapter 6. Brisbane (AU): Exon Publications; 2021
• 4 Puccini B, Nassi L, Minoia C. et al. Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography. Ann Hematol 2017; 96: 1147-1153
• 5 Öner AO, Sürer Budak E, Aydın F. et al. Efficacy of 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computerized Tomography for Bone Marrow Infiltration Assessment in the Initial Staging of Lymphoma. Mol Imaging Radionucl Ther 2017; 26: 69-75
• 6 Cistaro A, Cassalia L, Ferrara C. et al. Italian Multicenter Study on Accuracy of 18F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk 2018; 18: 267-273
• 7 Bain BJ. Bone marrow biopsy morbidity and mortality: 2002 data. Clin Lab Haematol 2004; 26: 315-318
• 8 Zhang QY, Foucar K. Bone Marrow Involvement by Hodgkin and Non-Hodgkin Lymphomas. Hematol Oncol Clin North Am 2009; 23: 873-902
• 9 Shankar A, Fiumara F, Pinkerton R. Role of FDG PET in the management of childhood lymphomas – case proven or is the jury still out?. Eur J Cancer 2008; 44: 663-673
• 10 Cerci JJ, Bogoni M, Buccheri V. et al. Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin’s lymphoma. Results from Brazilian Hodgkin’s Lymphoma Study Group. Hematol Transfus Cell Ther 2018; 40: 245-249
• 11 Hutchings M, Loft A, Hansen M. et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 2006; 91: 482-489
• 12 Juweid ME, Stroobants S, Hoekstra OS. et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578
• 13 Voltin CA, Goergen H, Baues C. et al. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann Oncol 2018; 29: 1926-1931
• 14 Purz S, Mauz-Körholz C, Körholz D. et al. [18F] fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. J Clin Oncol 2011; 29: 3523-3528
• 15 El-Galaly TC, d’Amore F, Mylam KJ. et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012; 30: 4508-4514
• 16 Adams HJA, Kwee TC, de Keizer B. et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?. Ann Oncol 2014; 25: 921-927
• 17 Cheng G, Alavi A. Value of 18F-FDG PET versus iliac biopsy in the initial evaluation of bone marrow infiltration in the case of Hodgkin’s disease: A meta-analysis. Nucl Med Commun 2013; 34: 25-31
• 18 Kim K, Kim SJ. Diagnostic performance of F-18 FDG PET/CT in the detection of bone marrow involvement in paediatric hodgkin lymphoma: A meta-analysis. Leuk Res 2021; 102: 106525
• 19 Agool A, Glaudemans AWJM, Boersma HH. et al. Radionuclide imaging of bone marrow disorders. Eur J Nucl Med Mol Imaging 2011; 38: 166-178
• 20 Salaun PY, Gastinne T, Bodet-Milin C. et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: A reflection of disease infiltration or just inflammation?. Eur J Nucl Med Mol Imaging 2009; 36: 1813-1821
• 21 Do Vale RHB, Ferraro DA, Duarte PS. et al. Bone marrow uptake of 18F-fluorodeoxyglucose in Hodgkin lymphoma without bone involvement: Comparison between patients with and without B symptoms. Radiol Bras 2018; 51: 76-180
• 22 Hashmi HRT, Mishra R, Niazi M. et al. An unusual triad of hemophagocytic syndrome, lymphoma and tuberculosis in a non-HIV patient. Am J Case Rep 2017; 18: 739-745
• 23 Kaae J, Nørgaard P, Himmelstrup B. Visceral leishmaniasis diagnosed in a patient with MALT lymphoma. Eur J Intern Med 2007; 18: 235-237
• 24 Ruiz e Resende LS, Yasuda AG, Mendes RP. et al. Paracoccidioidomycosis in Patients with Lymphoma and Review of Published Literature. Mycopathologia 2015; 179: 285-291